AngioDynamics, Inc. (ANGO) Analysts See $0.20 EPS

March 21, 2018 - By Marguerite Chambers

 AngioDynamics, Inc. (ANGO) Analysts See $0.20 EPS
Investors sentiment decreased to 1.17 in 2017 Q3. Its down 1.32, from 2.49 in 2017Q2. It turned negative, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Swiss Financial Bank, a Switzerland-based fund reported 61,000 shares. 65,557 are held by Legal & General Gp Public Ltd Company. Assetmark Inc invested in 266 shares. Goldman Sachs Grp Inc Inc, a New York-based fund reported 282,250 shares. Dimensional Fund Advsrs Lp holds 0.02% or 3.09 million shares in its portfolio. One National Association reported 0.11% stake. Peak6 Lp stated it has 13,895 shares or 0% of all its holdings. California Public Employees Retirement Systems reported 196,202 shares. Thomson Horstmann And Bryant has 0.7% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 298,128 shares. First Quadrant Ltd Partnership Ca holds 0.02% or 55,159 shares. Sterling Cap Ltd Liability stated it has 37,524 shares. Ameriprise Fincl invested in 639,011 shares or 0.01% of the stock. Sentinel Asset Management invested in 0.34% or 824,201 shares. 495,133 are held by Natl Bank Of New York Mellon Corporation. Rothschild Asset Management stated it has 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO).

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35M giving it 20.95 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock decreased 0.18% or $0.03 during the last trading session, reaching $16.76. About 391 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 21, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. As per Thursday, January 4, the company rating was maintained by Canaccord Genuity. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) rating on Friday, January 8. Canaccord Genuity has “Buy” rating and $14.5 target. The firm has “Hold” rating given on Monday, July 10 by Canaccord Genuity. The firm has “Sell” rating by Zacks given on Monday, August 31. The rating was maintained by Canaccord Genuity on Sunday, October 8 with “Hold”. Craig Hallum downgraded the stock to “Hold” rating in Friday, January 5 report. Canaccord Genuity maintained the shares of ANGO in report on Monday, September 4 with “Hold” rating. The firm earned “Buy” rating on Friday, November 4 by Cantor Fitzgerald. The firm has “Equal-Weight” rating given on Wednesday, July 19 by Barclays Capital. As per Thursday, August 24, the company rating was maintained by KeyBanc Capital Markets.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $615.85 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: